ResMed set to raise up to $172.5 million
This article was originally published in Clinica
Executive Summary
ResMed, which makes and sells equipment for the diagnosis and treatment of sleep-disordered breathing, plans to raise $150 million through a private placement of its convertible subordinated notes, due 2006. The New York company says it may increase its sale by $22.5 million if there is sufficient demand. It plans to use part of the proceeds to pay down debt taken on to buy MAP Medizin-Technologie in February.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.